首页> 外文OA文献 >Dietary supplements and risk of cause-specific death, cardiovascular disease, and cancer: a protocol for a systematic review and network meta-analysis of primary prevention trials
【2h】

Dietary supplements and risk of cause-specific death, cardiovascular disease, and cancer: a protocol for a systematic review and network meta-analysis of primary prevention trials

机译:膳食补充剂和因特定原因死亡,心血管疾病和癌症的风险:对一级预防试验进行系统回顾和网络荟萃分析的方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: In the Western world, dietary supplements are commonly used to prevent chronic diseases, mainly cardiovascular disease and cancer. However, there is inconsistent evidence on which dietary supplements actually lower risk of chronic disease, and some may even increase risk. We aim to evaluate the comparative safety and/or effectiveness of dietary supplements for the prevention of mortality (all-cause, cardiovascular, and cancer) and cardiovascular and cancer incidence in primary prevention trials. Methods/Design: We will search PubMed, EMBASE, Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Cochrane Central Register of Controlled Trials, clinical trials.gov, and the World Health Organization International Trial Registry Platform. Randomized controlled trials will be included if they meet the following criteria: (1) minimum intervention period of 12 months; (2) primary prevention of chronic disease (is concerned with preventing the onset of diseases and conditions); (3) minimum mean age ≥18 years (maximum mean age 70 years); (4) intervention(s) include vitamins (beta-carotene, vitamin A, B vitamins, Vitamin C, Vitamin D, Vitamin E, and multivitamin supplements); fatty acids (omega-3 fatty acids, omega-6 fatty acids, monounsaturated fat); minerals (magnesium, calcium, selenium, potassium, iron, zinc, copper, iodine; multiminerals); supplements containing combinations of both vitamins and minerals; protein (amino acids); fiber; prebiotics; probiotics; synbiotics; (5) supplements are orally administered as liquids, pills, capsules, tablets, drops, ampoules, or powder; (6) report results on all-cause mortality (primary outcome) and/or mortality from cardiovascular disease or cancer, cardiovascular and/or cancer incidence (secondary outcomes). Pooled effects across studies will be calculated using Bayesian random effects network meta-analysis. Sensitivity analysis will be performed for trials lasting ≥5 years, trials with low risk of bias, trials in elderly people (≥65 years), ethnicity, geographical region, and trials in men and women. The results of the corresponding fixed effects models will also be compared in sensitivity analyses. Discussion: This is a presentation of the study protocol only. Results and conclusions are pending completion of this study. Our systematic review will be of great value to consumers of supplements, healthcare providers, and policy-makers, regarding the use of dietary supplements.
机译:背景:在西方世界,膳食补充剂通常用于预防慢性疾病,主要是心血管疾病和癌症。但是,关于哪些膳食补充剂实际上降低了患慢性病的风险,甚至还有可能增加患病风险的证据并不一致。我们旨在评估一级预防试验中膳食补充剂在预防死亡率(全因,心血管和癌症)以及心血管和癌症发病率方面的相对安全性和/或有效性。方法/设计:我们将搜索PubMed,EMBASE,Cochrane系统评价数据库,效果评价摘要数据库,Cochrane对照试验中央注册系统,clinical trials.gov和世界卫生组织国际试验注册平台。如果符合以下标准,则将包括随机对照试验:(1)最小干预期为12个月; (2)慢性疾病的初级预防(与预防疾病和病症的发作有关); (3)最小平均年龄≥18岁(最大平均年龄70岁); (4)干预措施包括维生素(β-胡萝卜素,维生素A,B维生素,维生素C,维生素D,维生素E和多种维生素补充剂);脂肪酸(omega-3脂肪酸,omega-6脂肪酸,单不饱和脂肪);矿物质(镁,钙,硒,钾,铁,锌,铜,碘;多矿物质);含有维生素和矿物质的组合的补品;蛋白质(氨基酸);纤维;益生元益生菌合生素; (5)补品以液体,丸剂,胶囊剂,片剂,滴剂,安瓿或粉剂形式口服; (6)报告全因死亡率(主要结局)和/或心血管疾病或癌症导致的死亡率,心血管和/或癌症发病率(次要结局)的结果。跨研究的合并效应将使用贝叶斯随机效应网络荟萃分析进行计算。将对持续时间≥5年的试验,偏倚风险低的试验,老年人(≥65岁)的试验,种族,地理区域以及男女试验进行敏感性分析。相应的固定效应模型的结果也将在灵敏度分析中进行比较。讨论:这仅是研究方案的介绍。结果和结论有待完成本研究。对于膳食补充剂的使用,我们的系统评价对补充剂的消费者,保健提供者和政策制定者具有重要价值。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号